Mereo BioPharma Group plc (MREO) — research page
US · us-cm-kg/NASDAQ/MREO · as of 2026-11-08
Identity and listing
The issuer is Mereo BioPharma Group plc, listed on NASDAQ under ticker MREO, with ISIN US5894921072 and LEI 213800U8JQHIJOS5AS09. Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United Kingdom. The issuer is listed and not halted.
| field | value | source · read date |
|---|---|---|
| name | Mereo BioPharma Group plc | source · 2026-11-08 |
| exchange | NASDAQ | source · 2026-11-08 |
| ticker | MREO | source · 2026-11-08 |
| ISIN | US5894921072 | source · 2026-10-13 |
| LEI | 213800U8JQHIJOS5AS09 | source · 2026-11-08 |
| security type | Corporate | source · 2026-11-08 |
| segment | not on the record | |
| sector | 2834 Pharmaceutical Preparations | source · 2026-11-08 |
| jurisdiction | United Kingdom | source · 2026-11-08 |
| status | listed, not halted | source · 2026-11-08 |
The disclosure read
The record holds 44 filings in the twelve months to 2026-11-08, across 20 filing days. The median gap between filing days is 8 days. The latest filing is dated 2026-10-28, 11 days before the record date, and is of type regulatory_filing. On NASDAQ the median cadence gap is 6.0 days, the median filings count is 52, and the median latency is 5.0 days across 4359 issuers. On 2834 Pharmaceutical Preparations the median cadence gap is 6.0 days, the median filings count is 63.0, and the median latency is 4.0 days across 526 issuers.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 44 | 8 | 11 |
| exchange median: NASDAQ (4359 issuers) | 52 | 6 | 5 |
| sector median: 2834 Pharmaceutical Preparations (526 issuers) | 63 | 6 | 4 |
| date | type | category | filing |
|---|---|---|---|
| 2026-10-28 | regulatory_filing | SCHEDULE 13G/A | SCHEDULE 13G/A |
| 2026-08-19 | halt_suspension | 8-K | 8-K — 8-K (items 3.01) |
| 2026-08-14 | regulatory_filing | SCHEDULE 13G/A | SCHEDULE 13G/A |
| 2026-08-11 | results | 10-Q | 10-Q — 10-Q |
| 2026-08-11 | results | 8-K | 8-K — 8-K (items 2.02,9.01) |
window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor's location is not on the record. The record holds no auditor changes.
Events and halts
The record holds no listing, delisting, name change or segment move lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted.
Orderability
The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.
rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The issuer's investor-relations page names 9 research houses: Baird, BTIG, Cantor Fitzgerald, Jefferies, JP Morgan, Leerink Partners, LifeSci Capital, Needham and Van Lanschot Kempen.
| research house | analyst | source · read date |
|---|---|---|
| Baird | Jack Allen, CFA | issuer page · 2026-11-11 |
| BTIG | Julian Harrison | issuer page · 2026-11-11 |
| Cantor Fitzgerald | Kristen Kluska | issuer page · 2026-11-11 |
| Jefferies | Maury Raycroft, Ph.D. | issuer page · 2026-11-11 |
| JP Morgan | Priyanka Gover, Ph.D. Anupam Rama | issuer page · 2026-11-11 |
| Leerink Partners | Joseph Schwartz | issuer page · 2026-11-11 |
| LifeSci Capital | Katherine Dellorusso, Ph.D. | issuer page · 2026-11-11 |
| Needham | Gil Blum, Ph.D. | issuer page · 2026-11-11 |
| Van Lanschot Kempen | Sebastiaan van der Schoot, Ph.D. | issuer page · 2026-11-11 |
Open research
No openly published research notes were found on the record.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for the issuer. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.
Sources
9 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)
- 10.2
- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)
- 10.3
- https://data.sec.gov/submissions/CIK0001719714.json (identity.jurisdiction)
- 10.4
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.5
- https://mcp.us-cm-kg.ai/events/NASDAQ/MREO (the disclosure lines)
- 10.6
- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)
- 10.7
- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.8
- https://www.mereobiopharma.com/investors/ (coverage)
- 10.9
- https://mcp.us-cm-kg.ai/record/NASDAQ/MREO (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"US5894921072"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:9761eeb11cab2319.